Free Trial

Voyager Therapeutics (VYGR) Stock Forecast & Price Target

Voyager Therapeutics logo
$5.75 +0.06 (+1.05%)
(As of 12/20/2024 05:17 PM ET)

Voyager Therapeutics - Analysts' Recommendations and Stock Price Forecast (2025)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Sell
0
Hold
0
Buy
9

Based on 9 Wall Street analysts who have issued ratings for Voyager Therapeutics in the last 12 months, the stock has a consensus rating of "Buy." Out of the 9 analysts, 8 have given a buy rating, and 1 has given a strong buy rating for VYGR.

Consensus Price Target

$17.00
195.65% Upside
According to the 9 analysts' twelve-month price targets for Voyager Therapeutics, the average price target is $17.00. The highest price target for VYGR is $30.00, while the lowest price target for VYGR is $11.00. The average price target represents a forecasted upside of 195.65% from the current price of $5.75.
Get the Latest News and Ratings for VYGR and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for Voyager Therapeutics and its competitors.

Sign Up

VYGR Analyst Ratings Over Time

TypeCurrent Forecast
12/22/23 to 12/21/24
1 Month Ago
11/22/23 to 11/21/24
3 Months Ago
9/23/23 to 9/22/24
1 Year Ago
12/22/22 to 12/22/23
Strong Buy
1 Strong Buy rating(s)
1 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
Buy
8 Buy rating(s)
7 Buy rating(s)
5 Buy rating(s)
2 Buy rating(s)
Hold
0 Hold rating(s)
1 Hold rating(s)
1 Hold rating(s)
1 Hold rating(s)
Sell
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
Consensus Price Target$17.00$17.00$17.83$17.00
Forecasted Upside195.65% Upside213.08% Upside185.33% Upside100.47% Upside
Consensus Rating
Buy
Buy
Moderate Buy
Moderate Buy

VYGR Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

VYGR Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

Voyager Therapeutics Stock vs. The Competition

TypeVoyager TherapeuticsMedical CompaniesS&P 500
Consensus Rating Score
3.11
2.81
2.51
Consensus RatingBuyModerate BuyModerate Buy
Predicted Upside195.65% Upside25,828.59% Upside14.54% Upside
News Sentiment Rating
Neutral News

See Recent VYGR News
Positive News
Positive News
DateBrokerageAnalyst NameActionRatingPrice TargetUpside/Downside on Report DateDetails
12/2/2024Citigroup
3 of 5 stars
 Initiated CoverageBuy$12.00+74.93%
11/29/2024Wedbush
4 of 5 stars
Y. Zhong
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageOutperform$7.00 ➝ $11.00+90.31%
11/14/2024Canaccord Genuity Group
1 of 5 stars
 Reiterated RatingBuy ➝ Buy$14.00 ➝ $14.00+112.44%
11/14/2024HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingBuy ➝ Buy$30.00 ➝ $30.00+348.43%
10/16/2024Leerink Partnrs
Subscribe to MarketBeat All Access for the recommendation accuracy rating
L. Nsongo
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeStrong-Buy
10/16/2024Leerink Partners
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageOutperform$15.00+118.98%
5/15/2024Oppenheimer
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingOutperform ➝ Outperform$18.00+110.77%
3/26/2024Guggenheim
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageBuy$22.00+137.58%
1/2/2024Wells Fargo & Company
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 UpgradeEqual Weight ➝ Overweight$9.00 ➝ $14.00+35.14%
9/18/2023Chardan Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
G. Livshits
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingNeutral
5/10/2023Truist Financial
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageBuy$18.00+67.29%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Saturday at 08:42 PM ET.


VYGR Forecast - Frequently Asked Questions

According to the research reports of 9 Wall Street equities research analysts, the average twelve-month stock price forecast for Voyager Therapeutics is $17.00, with a high forecast of $30.00 and a low forecast of $11.00.

9 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Voyager Therapeutics in the last year. There are currently 8 buy ratings and 1 strong buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" VYGR shares.

According to analysts, Voyager Therapeutics's stock has a predicted upside of 195.65% based on their 12-month stock forecasts.

Over the previous 90 days, Voyager Therapeutics's stock had 1 upgrade by analysts.

Voyager Therapeutics has been rated by research analysts at Canaccord Genuity Group, Citigroup, HC Wainwright, Leerink Partners, Leerink Partnrs, and Wedbush in the past 90 days.

Analysts like Voyager Therapeutics more than other "medical" companies. The consensus rating for Voyager Therapeutics is Buy while the average consensus rating for "medical" companies is Moderate Buy. Learn more on how VYGR compares to other companies.


This page (NASDAQ:VYGR) was last updated on 12/21/2024 by MarketBeat.com Staff
From Our Partners